| James Glenn Rogers, PSYSD | |
|
1605 Danielson Rd, Kalispell, MT 59901-7252 | |
| (406) 758-8124 | |
| Not Available |
| Full Name | James Glenn Rogers |
|---|---|
| Gender | Male |
| Speciality | Psychologist |
| Location | 1605 Danielson Rd, Kalispell, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912170945 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 326 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Glenn Rogers, PSYSD 1605 Danielson Rd, Summit Preparatory School, Kalispell, MT 59901-7252 Ph: (406) 758-8124 | James Glenn Rogers, PSYSD 1605 Danielson Rd, Kalispell, MT 59901-7252 Ph: (406) 758-8124 |
News Archive
Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) in the European Union, for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control.
Today, the most common childhood cancer is cured in about 80 percent of patients; only forty years ago, this number was closer to five percent. In efforts to further increase the survival rate, researchers from St. Jude Children's Research Hospital, the University of Tennessee, and the University of Chicago studied how an individual's genetics might play a role in the effectiveness of chemotherapy drugs.
Researchers from Boston University School of Medicine and Boston Medical Center have found that by adding one family physician per 1,000, or 100 per 100,000, could reduce hospital readmission costs by $579 million per year, or 83 percent of the Patient Protection and Affordable Care Act (ACA) target. These findings currently appear on the website of the "Robert Graham Center," a primary care think tank.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
› Verified 7 days ago
Dr. Shari Schindel, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 185 Cheviot Loop, Kalispell, MT 59901 Phone: 406-314-4052 | |
Barbara Louise Stone, PH.D PSYCHOLOGIST Psychologist Medicare: Not Enrolled in Medicare Practice Location: 432 E Idaho St, Kalispell, MT 59901 Phone: 406-257-1623 Fax: 406-494-1724 | |
Dr. Katrina Kit Evans, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1075 N Meridian Rd Ste 200, Kalispell, MT 59901 Phone: 406-351-4052 | |
Herman J Androes, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 465 Leisure Dr, Kalispell, MT 59901 Phone: 406-752-3413 | |
Dr. Patricia Greene Hall, PH.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1035 1st Ave W Fl 3, Kalispell, MT 59901 Phone: 406-758-2172 | |
Dr. Angela Jez, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 723 5th Ave E, Suite 110 C, Kalispell, MT 59901 Phone: 406-755-4427 Fax: 406-755-4329 | |
Meghan Gill, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 40 2nd St E Ste 230, Kalispell, MT 59901 Phone: 406-282-1576 |